The multinational, double-blind, placebo-controlled trial will last 26 weeks and will enroll 200 patients with moderate to severe chronic plaque psoriasis with fingernail psoriasis. The primary endpoints will be evaluated after 26 weeks and will assess the percent of patients who achieve a Physicians Global Assessment of Fingernail Psoriasis (PGA-F) of either “clear” or “minimal”. It will also evaluate the percent of patients who achieve a 75% reduction in fingernail psoriasis, as defined by the modified Nail Psoriasis Severity Index (mNAPSI).
Humira is a TNF blocker currently indicated to reduce the signs and symptoms of moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn’s disease; to induce remission in moderate-to-severe ulcerative colitis; and to treat moderate-to-severe chronic plaque psoriasis.
For more information call (800) 633-9110 or visit Humira.com.